Your browser doesn't support javascript.
loading
Evaluation of Time to Therapeutic Anticoagulation and Associated Outcomes in Critically Ill, Obese Patients With Pulmonary Embolism Receiving Unfractionated Heparin.
Sutton, Lauren H; Tellor, Bethany R; Pope, Hannah E; Riney, Jennifer N; Weaver, Katherine L.
Afiliação
  • Sutton LH; Department of Pharmacy, 21737Barnes-Jewish Hospital, Saint Louis, MO, USA.
  • Tellor BR; Department of Pharmacy, 21737Barnes-Jewish Hospital, Saint Louis, MO, USA.
  • Pope HE; Department of Pharmacy, 21737Barnes-Jewish Hospital, Saint Louis, MO, USA.
  • Riney JN; Department of Pharmacy, 21737Barnes-Jewish Hospital, Saint Louis, MO, USA.
  • Weaver KL; Department of Pharmacy, 5170University of Louisville Hospital, Louisville, KY, USA.
J Pharm Pract ; 34(3): 438-444, 2021 Jun.
Article em En | MEDLINE | ID: mdl-31564199
BACKGROUND: Delays in time to therapeutic activated partial thromboplastin time (aPTT) have been associated with poor outcomes in patients with acute pulmonary embolism (PE). OBJECTIVE: To investigate the relationship between time to therapeutic anticoagulation and in-hospital mortality in critically ill, obese patients with acute PE. METHODS: This study examined 204 critically ill patients with a body mass index (BMI) ≥30 kg/m2 receiving unfractionated heparin (UFH) for PE treatment. Patients achieving therapeutic anticoagulation within 24 hours of UFH initiation (early) were compared to those in >24 hours (delayed). Additional end points included 30-day mortality, median time to therapeutic aPTT, proportion of therapeutic and supratherapeutic aPTT values, hemodynamic deterioration, thrombolytic therapy after UFH initiation, length of stay, and bleeding. RESULTS: No difference in in-hospital or 30-day all-cause mortality was seen (odds ratio [OR]: 1.33, confidence interval [CI]: 0.647-2.72; OR: 1.003, CI: 0.514-1.96). Patients in the early group had a greater proportion of therapeutic aPTT values (66.7% vs 50%, P < .001) and higher percentage of supratherapeutic aPTT values (20.9% vs 11.3%, P < .001); however, no increase in clinically significant bleeding was evident (15.2% vs 10.9%, P = .366). CONCLUSION: In this population, a shorter time to therapeutic aPTT was not associated with improved survival.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Embolia Pulmonar / Heparina Tipo de estudo: Diagnostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Pharm Pract Assunto da revista: FARMACIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Embolia Pulmonar / Heparina Tipo de estudo: Diagnostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Pharm Pract Assunto da revista: FARMACIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos